GLPwatch
In type 2 diabetes with increased CV risk, tirzepatide reduced HbA<sub>1c</sub> vs. glargine at 52 wk.
Ann Intern Med · 2022
Last updated 2026-05-28In a study of 1,877 adults with type 2 diabetes and increased cardiovascular risk, tirzepatide reduced blood sugar control (measured by HbA1c) more than glargine over 52 weeks. The average starting HbA1c was 8.26%, and the average reduction was 2.19% with tirzepatide compared to 1.44% with glargine.
AI summary of the abstract below.
| Journal | Ann Intern Med, 2022 |
|---|---|
| Citations | 2 |
| Relative citation ratio | 0.11 |
| NIH percentile | 8 |
| Molecules | tirzepatide |
| Conditions studied | Type 2 Diabetes, Cardiovascular Risk Reduction |
Abstract
Del Prato S, Kahn SE, Pavo I, et al. Lancet. 2021;398:1811-24. 34672967.
Verbatim abstract via PubMed 35226523 ↗
Related research
- Tirzepatide Once Weekly for the Treatment of Obesity.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
- Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
- Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.